Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation

被引：6
|
作者：
Wang, Dongxu [1 ]
Dai, Da-Peng [2 ]
Wu, Hualan [1 ]
Chong, Jia [1 ]
Lu, You [1 ]
Yin, Ruoyun [1 ]
Zhao, Xinlong [1 ]
Zhao, Anxu [1 ]
Yang, Jiefu [1 ]
Chen, Hao [1 ]
机构：
[1] Beijing Hosp, Cardiovasc Dept, Natl Ctr Gerontol, Beijing 100730, Peoples R China
[2] Beijing Hosp, Natl Ctr Gerontol, Key Lab Geriatr, Beijing 100730, Peoples R China
来源：
PHARMACOGENOMICS | 2020年 / 21卷 / 14期
基金：
美国国家科学基金会;
关键词：
atrial fibrillation; gene polymorphism; warfarin-dosing algorithm; warfarin; GENETIC-VARIANTS; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; CYP2C9-ASTERISK-13; ALLELE; GENOTYPE; VKORC1; IDENTIFICATION; REQUIREMENT; PHARMACOKINETICS; ANTICOAGULATION;
D O I：
10.2217/pgs-2020-0051
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim:Gene polymorphisms are critical in warfarin dosing variation. Here, the role of rareCYP2C9alleles on warfarin doses in Chinese Han patients was investigated.Methods:A retrospective study recruited 681 warfarin treated atrial fibrillation patients. The genetic and clinical data were collected. Dose-related variables were selected by univariate analyses and the warfarin-dosing algorithm was derived by multivariate regression analysis.Results:Three rareCYP2C9alleles (CYP2C9*13, *16 and *60) were associated with lower stable doses. Inclusion of the rareCYP2C9alleles in the prediction model added an extra 3.7% warfarin dose predictive power.Conclusion:CYP2C9*13, *16 and *60 was associated with lower stable warfarin doses in Chinese patients. The algorithm including rareCYP2C9alleles tends to more accurately predict stable warfarin doses.
引用
收藏
页码：1021 / 1031
页数：11
相关论文
共 50 条
  • [21] Warfarin Dosing in Patients with the CYP2C9*5 Variant
    Lindley, Kathryn
    Limdi, Nita
    Cavallari, Larisa H.
    Perera, Minoli
    Lenzini, Petra
    Johnson, Julie
    Wu, Alan
    Ridker, Paul
    Patel, Shitalben
    King, Cristi
    Shah, Shimoli
    Eby, Charles
    Beasley, T. Mark
    Gage, Brian F.
    CIRCULATION, 2010, 122 (21)
  • [22] Warfarin therapy in a patient homozygous for the CYP2C9*3 allele
    Ablin, J
    Cabili, S
    Lagziel, A
    Peretz, H
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (02): : 139 - 141
  • [23] Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement
    Chen, Weirong
    Wu, Luhua
    Liu, Xin
    Shen, Yue
    Liang, Yan
    Zhu, Jun
    Tan, Huiqiong
    Yang, Yanmin
    Liu, Qun
    Wang, Mingsheng
    Liu, Lisheng
    Wang, Xingyu
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (02) : 126 - 132
  • [24] Should We Test for CYP2C9 Before Initiating Anticoagulant Therapy in Patients with Atrial Fibrillation?
    Mark H. Eckman
    Steven M. Greenberg
    Jonathan Rosand
    Journal of General Internal Medicine, 2009, 24 : 543 - 549
  • [25] Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin
    Pavani, Addepalli
    Naushad, Shaik Mohammad
    Stanley, Balraj Alex
    Kamakshi, Renganathan Gnanambal
    Abinaya, Krishnan
    Rao, Malempati Amaresh
    Uma, Addepally
    Kutala, Vijay Kumar
    PHARMACOGENOMICS, 2015, 16 (04) : 393 - 400
  • [26] Should We Test for CYP2C9 Before Initiating Anticoagulant Therapy in Patients with Atrial Fibrillation?
    Eckman, Mark H.
    Greenberg, Steven M.
    Rosand, Jonathan
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 (05) : 543 - 549
  • [27] Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7-Hydroxy Warfarin in South Indian Patients
    Kumar, Dhakchinamoorthi Krishna
    Uppugunduri, Chakradhara Rao Satyanarayana
    Shewade, Deepak Gopal
    Chandran, Sai B., V
    Adithan, Chandrasekaran
    CURRENT DRUG METABOLISM, 2021, 22 (12) : 989 - 995
  • [28] Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics
    Lee, H. W.
    Lim, M. -S.
    Lee, J.
    Jegal, M. -Y.
    Kim, D. -W.
    Lee, W. -K.
    Jang, I. -J.
    Shin, J. -G.
    Yoon, Y. -R.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (01) : 105 - 111
  • [29] Lessons learned from the influence of CYP2C9 genotype on warfarin dosing
    Tidbury, Nicola
    Preston, Joshua
    Lip, Gregory Y. H.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (04) : 185 - 188
  • [30] CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia
    Ngow, H. A.
    Khairina, Wan W. M. N.
    Teh, L. K.
    Lee, W. L.
    Harun, R.
    Ismail, R.
    Salleh, M. Z.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (05) : 490 - 493
12345